Biologics

The growth in complex biologics is boosting the demand for innovative delivery mechanisms such as prefilled drug-delivery systems. Unfortunately, these systems often encounter issues with particulates …

Natalizumab, which is currently being marketed by Biogen, is a humanized monoclonal antibody against the cell adhesion molecule ?4-integrin. It is a disease-modifying therapy for RRMS. …

Osbourn has over 30 years’ experience in biologics discovery and development. Most recently, she was Vice President for Research and Development and Site Leader at MedImmune …

Mr. Pollano has more than 25 years of industry experience, including senior management positions in global CDMOs. Federico Pollano succeeds Dr. Christoph Winterhalter, who has left …

The team headed by Devon Taylor identified a set of CD4-positive T-cells, which express the protein inducible costimulator (ICOS) in human skin, which contributes to systemic …

Mr. Larkin brings to SP broad experience as a senior executive having spent the last 27 years in commercial and executive leadership roles in the medical …

The deal includes the  acute lymphoblastic leukemia (ALL) drug pegaspargase (Oncaspar) and late stage ALL candidate drug calaspargase pegol plus the ex-US rights fort a nano-formulation of the …

GMP and new processes: be prepared for hassle Source link

The company reported promising 2-year overall survival data for its RAS mutations-targeting cancer jab TG01. Targovax’ CFO Erik Wiklund presented data showing that 90% of patients …

The takeover of Shire is the largest acquisition in Takeda’s history. Under the agreement, Takeda will pay  US$66, per share US$30.33 in cash and 0.839 Takeda …